Connect your AI

CG Oncology CGON Other Working Capital

Other Working Capital at other companies

ImmunityBio, Inc.IBRX

$16K-93.4%

Tango TherapeuticsTNGX

-$21K-138%

ExelixisEXEL

$2.02M-57.8%

CRISPR TherapeuticsCRSP

-$8.8M-291%

BiogenBIIB

$89M+66.4%

IncyteINCY

-$12.77M-141%

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.39B+206%

Enterprise value$5.36B+212%

P/S1,062.4×-1,596×

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's other working capital?: CG Oncology (CGON) reported other working capital of -$46K in Q1 2026.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.